Since the study showed high expression of PRDX5 and Nrf2 tightly associated with tumor size, clinical TNM stage, lymph node infiltration, etc, and predicted poor prognosis, we used Nrf2 and PRDX5 shRNA as therapeutic targets for tumor growth in vivo and achieved good results. This evidence concerns the gene PRDX5 and neoplasm.